| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3186578 | Annales de Dermatologie et de Vénéréologie | 2014 | 5 Pages |
Abstract
The patients treated by BRAF inhibitors (vemurafenib and dabrafenib) can present acantholytic dyskeratosis. The arisen of this mild dermatosis does not question, of course, the continuation of the treatment. These cutaneous manifestations can be managed with emollients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
M. Sabatier-Vincent, J. Charles, N. Pinel, I. Challende, A. Claeys, M.-T. Leccia,